In which trimester does Antiphospholipid (Apla) syndrome most commonly cause recurrent abortions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Antiphospholipid Syndrome and Recurrent Abortion by Trimester

Antiphospholipid syndrome (APS) most commonly causes recurrent pregnancy loss in the first trimester, though it can affect all trimesters and is particularly associated with losses occurring after 10 weeks gestation.

Timing of Pregnancy Loss in APS

First Trimester Predominance

  • The majority of APS-related pregnancy losses occur in the first trimester, with studies showing that 7-25% of recurrent spontaneous abortions are attributable to APS as the main risk factor 1.
  • Women with three or more consecutive first trimester spontaneous abortions and antiphospholipid antibodies represent a significant clinical population, with treatment studies specifically targeting this group demonstrating 89.4% of pregnancies proceeding beyond the first trimester with appropriate therapy 2.
  • Unexplained miscarriages, especially those occurring after 10 weeks gestation, should raise particular suspicion for APS, as this timing pattern is characteristic of the syndrome 3.

Clinical Pattern Across Trimesters

  • While first trimester losses are most common, APS is characterized by recurrent fetal loss across all gestational ages, distinguishing it from other causes of miscarriage 4.
  • The syndrome manifests not only as early pregnancy loss but also as severe complications in later pregnancy including preeclampsia, fetal growth retardation, and placental insufficiency, with these complications occurring in approximately 50% of treated patients 4.
  • Fetal death can occur in the second and third trimesters as part of the APS clinical spectrum, though early losses remain more frequent 5.

Diagnostic Considerations

Key Clinical Indicators

  • Women presenting with recurrent miscarriages (particularly after 10 weeks), unexplained single miscarriage in the first trimester, history of thrombosis, intrauterine growth restriction, or preeclampsia are candidates for APS evaluation 3.
  • The most clinically important serologic markers are lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2-glycoprotein 1 antibodies 4.

Important Caveat

  • Association does not equal causation: the exact proportion of abortions directly caused by APS is difficult to estimate due to variable definitions of recurrent abortion, lack of standardized antibody assays, and author-dependent inclusion criteria based on antibody titers 1.

Treatment Implications by Trimester

  • Treatment with low molecular weight heparin and low-dose aspirin initiated as soon as pregnancy is confirmed represents the evidence-based standard, with continuation throughout pregnancy 4, 3.
  • The general failure rate of heparin/aspirin treatment is approximately 30%, with intravenous immunoglobulin reserved for refractory cases 4.
  • Treatment should begin immediately upon pregnancy confirmation and continue through all trimesters, as the risk extends beyond the first trimester despite the higher frequency of early losses 2, 5.

References

Research

Antiphospholipid syndrome and recurrent miscarriages.

European journal of obstetrics, gynecology, and reproductive biology, 2001

Research

Antiphospholipid syndrome in obstetrics.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2003

Research

The antiphospholipid syndrome: from pathophysiology to treatment.

Clinical and experimental medicine, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.